CivaTech Oncology, which is utilizing proprietary technology to develop improvements in radiation treatment, has won a second National Institutes of Health contract for a means to treat lung cancer.
The Phase II contract for $1 million is for the further development and commercialization of CivaTech’s CivaSheet product.
The device, which is bioabsorbable, is designed for direct administration of radiation in treatment of lung cancer.
CivaTech received a Phase I contract in 2010.
The company already has won regulatory approval for its CivaString product, which is designed for treatment of “localized” tumors.
“We are extremely proud to be among the organizations selected to receive a Phase II Contract,” said Suzanne Babcock, the co-founder and executive chairman of CivaTech. “Our company has dedicated itself to the mission of improving cancer therapy with novel polymer-based radiation sources that strive to maximize quality of life. We are very excited about the recognition and support provided by the National Institutes of Health and the National Cancer Institute and I would like to thank the members of our team who worked with enthusiasm and perseverance to make this possible.”
